The frequency of 4-1BB+ PD-1+ CD8 T cells in the tumor at baseline demonstrated a statistically significant separation of responders from non-responders (Fig. 5a-b), and validation of this finding using multicolor IHC is planned. The gene discussed is CD8A; the disease is neoplasm.